John J Albers
Overview
Explore the profile of John J Albers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klein T, Torres-Ruiz J, Albers J
Tree Physiol
. 2022 Jan;
42(4):722-726.
PMID: 35084498
The unprecedented heatwave which hit the Pacific northwest of North America in late June-early July 2021 impacted ecosystems and communities, yet evidence for and analysis of this impact are still...
2.
Lyubarova R, Albers J, Marcovina S, Yao Y, McBride R, Topliceanu A, et al.
J Cardiovasc Pharmacol Ther
. 2019 May;
24(6):534-541.
PMID: 31131629
Background: Lipoprotein-associated phospholipase A (LpPLA) is an inflammatory marker that has been associated with the presence of vulnerable plaque and increased risk of cardiovascular (CV) events. Objective: To assess the...
3.
Zhang M, Zhai X, Li J, Albers J, Vuletic S, Ren G
Biochim Biophys Acta Mol Cell Biol Lipids
. 2018 Jun;
1863(9):1082-1094.
PMID: 29883800
Human phospholipid transfer protein (PLTP) mediates the transfer of phospholipids among atheroprotective high-density lipoproteins (HDL) and atherogenic low-density lipoproteins (LDL) by an unknown mechanism. Delineating this mechanism would represent the...
4.
Zhao X, P Phan B, Davis J, Isquith D, Dowdy A, Boltz S, et al.
J Clin Lipidol
. 2016 Sep;
10(5):1091-7.
PMID: 27678425
Background: Cardiovascular disease (CVD) begins early in life and is associated with both the number of risk factors present and length of exposure to these risk factors including hyperlipidemia. Objectives:...
5.
Albers J, Slee A, Fleg J, OBrien K, Marcovina S
Atherosclerosis
. 2016 Jun;
251:454-459.
PMID: 27320173
Background And Aims: Previous results of the AIM-HIGH trial showed that baseline levels of the conventional lipid parameters were not predictive of future cardiovascular (CV) outcomes. The aims of this...
6.
Marcovina S, Albers J
J Lipid Res
. 2015 Dec;
57(4):526-37.
PMID: 26637278
The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific antibodies directed to apo(a) more difficult and...
7.
Deguchi H, Wolfbauer G, Cheung M, Banerjee Y, Elias D, Fernandez J, et al.
Thromb J
. 2015 Jul;
13:24.
PMID: 26185485
Background: Plasma phospholipid transfer protein (PLTP) transfers lipids between donors and acceptors (e.g., from HDL to VLDL) and modulates lipoprotein composition, size, and levels. No study has reported an assessment...
8.
Kim D, Burt A, Ranchalis J, Vuletic S, Vaisar T, Li W, et al.
J Lipid Res
. 2015 May;
56(7):1351-62.
PMID: 26009633
Recent studies have failed to demonstrate a causal cardioprotective effect of HDL cholesterol levels, shifting focus to the functional aspects of HDL. Phospholipid transfer protein (PLTP) is an HDL-associated protein...
9.
Kim D, Burt A, Rosenthal E, Ranchalis J, Eintracht J, Hatsukami T, et al.
J Am Heart Assoc
. 2014 Jun;
3(3):e000902.
PMID: 24965026
Background: Recent data suggest that high-density lipoprotein cholesterol (HDL-C) levels are likely not in the causative pathway of atheroprotection, shifting focus from HDL-C to its subfractions and associated proteins. This...
10.
Vuletic S, Kennedy H, Albers J, Killestein J, Vrenken H, Lutjohann D, et al.
Mult Scler Relat Disord
. 2014 Jun;
3(4):533-541.
PMID: 24955324
Apolipoprotein E (apoE), phospholipid transfer protein (PLTP) activity, lipids, total tau and beta amyloid 1-42 (Aβ) were measured in cerebrospinal fluid (CSF) from controls (n=38) and multiple sclerosis (MS) patients...